Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis
Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis
复制标题
DOI：
10.1016/j.bmc.2005.03.027
复制
发表时间：
2005-09-01
影响因子：
3.5
通讯作者：
Miyachi, H
中科院分区：
文献类型：
--
作者：
Hashimoto, Y;Miyachi, H
在这里，我们回顾了我们的研究，包括视黄酸受体（RAR）拮抗剂，维甲酸X受体（RXR）拮抗剂，雄激素受体（AR）拮抗剂，维生素D受体（VDR）拮抗剂的分子设计的基础上，抑制折叠的螺旋12，其中包含一个辅激活剂结合位点。对过氧化物酶体增殖物激活受体（PPAR）配体的结构研究进展进行了综述。(c)2005爱思唯尔有限公司保留所有权利。
Here we review our studies on the molecular design of nuclear receptor antagonists, including retinoic acid receptor (RAR) antagonists, retinoid X receptor (RXR) antagonists, androgen receptor (AR) antagonists, and vitamin D receptor (VDR) antagonists, based on inhibition of folding of helix 12, which contains a co-activator binding site. Recent progress in structural development studies of peroxisome proliferator-activated receptor (PPAR) ligands is also reviewed. (c) 2005 Elsevier Ltd. All rights reserved.